Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
Commentary|Videos|March 10, 2026
The Intersection of Breast and Gyn Cancer Treatments
Author(s)Natalie Berger, MD
Fact checked by: Paige Britt
See how breast cancer endocrine and targeted drugs inform endometrial and ovarian care—tamoxifen, CDK4/6 combos, and T-DXd.
Advertisement
In an interview with Targeted Oncology, Natalie Berger, MD, hematologist and oncologist at the New York Presbyterian Medical Group, discussed the commonalities in treating breast and gynecologic cancers regarding hormone-driven therapies.
Advertisement
Related to this article
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
Elinzanetant, already approved for menopause-related VMS, is being considered to address hot flashes associated with adjuvant breast cancer endocrine therapy.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
2
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
3
Denosumab Biosimilar Approved For Existing Oncology Indications
4
CEPHEUS and Frontline Treatment in Newly Diagnosed Multiple Myeloma
5